AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.38+0.01 (+0.01%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.93+6.16 (+1.97%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.25+8.87 (+1.38%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.15+3.71 (+0.75%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.95+1.59 (+0.73%) ▲|ORCL153.28+0.34 (+0.22%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM193.05+3.28 (+1.73%) ▲|QCOM184.30+7.42 (+4.19%) ▲|RTX197.50-0.62 (-0.31%) ▼|SBUX99.47+0.25 (+0.25%) ▲|SCHW106.44-0.89 (-0.83%) ▼|SO87.92+0.17 (+0.19%) ▲|SPG204.94+0.27 (+0.13%) ▲|T26.26+0.71 (+2.76%) ▲|TMO611.59+8.41 (+1.39%) ▲|TMUS183.07+5.91 (+3.34%) ▲|TSLA365.57+2.01 (+0.55%) ▲|TXN272.07+13.25 (+5.12%) ▲|UBER71.32-1.24 (-1.71%) ▼|UNH378.87-9.41 (-2.42%) ▼|UNP284.48-1.31 (-0.46%) ▼|UPS99.71-0.26 (-0.26%) ▼|USB62.69+0.28 (+0.44%) ▲|V370.08+2.87 (+0.78%) ▲|VZ50.68+0.71 (+1.42%) ▲|WFC90.27+0.82 (+0.92%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.53+0.30 (+0.18%) ▲|AAPL335.29+8.72 (+2.67%) ▲|ABBV256.43+1.43 (+0.56%) ▲|ABT101.74-1.62 (-1.57%) ▼|ACN180.17+2.26 (+1.27%) ▲|ADBE248.03-0.80 (-0.32%) ▼|AMAT463.70+9.69 (+2.13%) ▲|AMD517.08+13.48 (+2.68%) ▲|AMGN379.96-2.52 (-0.66%) ▼|AMT178.28+5.30 (+3.06%) ▲|AMZN255.90+4.01 (+1.59%) ▲|AVGO365.67+4.84 (+1.34%) ▲|AXP323.95+3.24 (+1.01%) ▲|BA209.03+4.23 (+2.07%) ▲|BAC62.77+0.21 (+0.34%) ▲|BKNG173.69-0.22 (-0.13%) ▼|BLK1,086.15+23.75 (+2.24%) ▲|BMY63.33-0.42 (-0.66%) ▼|BNY162.95+0.36 (+0.22%) ▲|BRK-B506.99-0.01 (0.00%) ▼|C138.49-0.01 (-0.01%) ▼|CAT821.43+16.43 (+2.04%) ▲|CL87.17-0.73 (-0.83%) ▼|CMCSA25.26+0.09 (+0.34%) ▲|COF207.32+0.21 (+0.10%) ▲|COP136.06-0.98 (-0.72%) ▼|COST903.31+0.93 (+0.10%) ▲|CRM248.33+5.33 (+2.19%) ▲|CSCO111.88+4.44 (+4.13%) ▲|CVS94.04-1.26 (-1.32%) ▼|CVX213.71+0.95 (+0.44%) ▲|DE685.84+7.90 (+1.17%) ▲|DHR200.47-0.07 (-0.03%) ▼|DIS106.92+1.10 (+1.04%) ▲|DUK119.38+0.01 (+0.01%) ▲|EMR150.99+2.62 (+1.77%) ▲|FDX311.14-0.66 (-0.21%) ▼|GD354.17-0.09 (-0.02%) ▼|GE323.91-0.25 (-0.08%) ▼|GEV951.57+27.66 (+2.99%) ▲|GILD143.66-1.15 (-0.79%) ▼|GM85.96-0.16 (-0.19%) ▼|GOOG338.74+8.35 (+2.53%) ▲|GOOGL341.70+9.10 (+2.74%) ▲|GS1,028.20+8.43 (+0.83%) ▲|HD309.33+3.64 (+1.19%) ▲|HON202.77+0.59 (+0.29%) ▲|IBM238.28+4.26 (+1.82%) ▲|INTC103.53+3.21 (+3.20%) ▲|INTU318.93+6.16 (+1.97%) ▲|ISRG367.64+7.18 (+1.99%) ▲|JNJ266.62+0.27 (+0.10%) ▲|JPM356.65+3.09 (+0.87%) ▲|KO88.00+0.17 (+0.19%) ▲|LIN464.70+3.08 (+0.67%) ▲|LLY1,120.39-2.62 (-0.23%) ▼|LMT524.42-5.71 (-1.08%) ▼|LOW197.49+0.90 (+0.46%) ▲|LRCX301.58+3.57 (+1.20%) ▲|MA567.37+2.00 (+0.35%) ▲|MCD252.95-0.10 (-0.04%) ▼|MDLZ62.27-0.20 (-0.32%) ▼|MDT90.38-1.24 (-1.35%) ▼|META653.25+8.87 (+1.38%) ▲|MMM163.88+1.02 (+0.62%) ▲|MO68.84+0.05 (+0.07%) ▲|MRK144.37-0.34 (-0.24%) ▼|MS213.45+0.79 (+0.37%) ▲|MSFT496.15+3.71 (+0.75%) ▲|MU978.44+1.03 (+0.11%) ▲|NEE82.37-0.07 (-0.08%) ▼|NFLX76.84+0.83 (+1.09%) ▲|NKE36.89+0.27 (+0.74%) ▲|NOW131.74+0.57 (+0.43%) ▲|NVDA219.95+1.59 (+0.73%) ▲|ORCL153.28+0.34 (+0.22%) ▲|PEP136.71+0.06 (+0.04%) ▲|PFE27.44-0.22 (-0.78%) ▼|PG144.00+1.03 (+0.72%) ▲|PLTR166.84+0.98 (+0.59%) ▲|PM193.05+3.28 (+1.73%) ▲|QCOM184.30+7.42 (+4.19%) ▲|RTX197.50-0.62 (-0.31%) ▼|SBUX99.47+0.25 (+0.25%) ▲|SCHW106.44-0.89 (-0.83%) ▼|SO87.92+0.17 (+0.19%) ▲|SPG204.94+0.27 (+0.13%) ▲|T26.26+0.71 (+2.76%) ▲|TMO611.59+8.41 (+1.39%) ▲|TMUS183.07+5.91 (+3.34%) ▲|TSLA365.57+2.01 (+0.55%) ▲|TXN272.07+13.25 (+5.12%) ▲|UBER71.32-1.24 (-1.71%) ▼|UNH378.87-9.41 (-2.42%) ▼|UNP284.48-1.31 (-0.46%) ▼|UPS99.71-0.26 (-0.26%) ▼|USB62.69+0.28 (+0.44%) ▲|V370.08+2.87 (+0.78%) ▲|VZ50.68+0.71 (+1.42%) ▲|WFC90.27+0.82 (+0.92%) ▲|WMT106.20+0.47 (+0.44%) ▲|XOM165.53+0.30 (+0.18%) ▲|
23.1 C
New York
Friday, September 11, 2026

Tag: rates

newssourceFORcompanyinformationcontent1releasesmarket

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

Evaluating Income Strategies to Enhance Social Security in Retirement Plans

Social Security is structured to replace approximately 40% of the average retiree's income, necessitating additional income sources to maintain one's standard of living. Annuities...

Fletcher Zone Maiden Mineral Resource of 2.3Moz

Stage 1 Fletcher Resource almost doubles the current Beta Hunt Resource PERTH, Western Australia, June 23, 2025 /CNW/ - Westgold Resources Limited (ASX: WGX) (TSX: WGX)...

Revolutionary Research by Dr. Takuma Hayashi Uncovers Molecular Origins of Deadly Uterine Cancer and Charts New Path for Treatment

In a landmark advancement for women's cancer research, Dr. Takuma Hayashi and his team have made groundbreaking discoveries that could transform our understanding and...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELV

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Broadmark Realty Capital Inc. of Class Action Lawsuit and Upcoming Deadlines...

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Broadmark Realty Capital Inc. ("Broadmark"...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility and actionable intelligence DENVER, June 22, 2025 /PRNewswire/ --...

Strategic Nest Egg Deployment for Optimal Retirement Income

The inquiry presents a classic challenge faced by many retirees: seeking maximum income with minimal risk. The financial landscape requires a disciplined approach, especially...

Debt Consolidation Loan for Poor Credit Score: Radcred Instant Funding Solution with No Credit Check & Same-Day Loan

Simplify your finances by consolidating high-interest debt into one low-interest loan. Apply today with Radcred for fast relief and better financial management. 
Simplify your finances by consolidating high-interest debt into one low-interest loan. Apply today with Radcred for fast relief and better financial management.

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRates

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers